Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
Alvotech 获得 FDA 批准 Selarsdi 治疗中度至重度斑块状牛皮癣
Alvotech receives FDA approval for Selarsdi for moderate to severe plaque psoriasis
Alvotech 获得 FDA 批准，将 Selarsdi 用于中度至重度斑块状牛皮癣
Adult patients with:
成年患者：
- moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)
- 适合光疗或全身疗法的中度至重度斑块状牛皮癣 (pSO)。(1.1)
- 活动性银屑病关节炎 (psA)。(1.2)
Pediatric patients 6 years and older with:
6 岁及以上的儿科患者：
- moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. (1.1)
- active psoriatic arthritis (PsA). (1.2)
- 中度至重度斑块状牛皮癣，适合光疗或全身治疗。（1.1）
- 活动性银屑病关节炎 (psA)。(1.2)
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。